Intellia Therapeutics Inc. NTLA
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform. The company focuses on developing treatments for genetically defined diseases by precisely editing disease-causing genes either directly inside the body (in vivo) or outside t…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees377
TickerNTLA
Statistics
Market Cap$1.83B
Revenue (TTM)$67.7M
Net Income-$412.7M
Net Margin-609.9%
EPS$-3.81
P/E-3.24
P/S26.11
P/B2.40
EV/EBITDA-3.48
ROE-56.3%
Dividend Yield—
Price$15.19
Data: Twelve Data · Revenue = mcap / P/S